Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Government-funded BiotechCorp Senior VP For Healthcare Selvam Ramaraj On Malaysia’s Biotech Expansion Plans: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Malaysia has identified the biotechnology industry as one of the key drivers of growth in transforming the country into a knowledge-based economy, and the government is fully committed to its development. As part of that commitment, the government set up the Malaysian Biotechnology Corporation (BiotechCorp) in 2005, as one of the action plans under the National Biotechnology Policy, under the purview of the Ministry of Science, Technology and Innovation. BiotechCorp's goal is to identify value propositions in both R&D and commerce and support these ventures via financial assistance and other means. BiotechCorp Senior Vice President for Healthcare Selvam Ramaraj recently talked with PharmAsia News about the company and its master plans for Malaysia.
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC071157

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel